Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1990 3
1991 2
1992 2
1994 4
1995 1
1996 1
1997 1
1998 1
1999 1
2000 1
2001 1
2002 4
2003 1
2004 1
2005 4
2006 4
2007 9
2008 15
2009 17
2010 18
2011 32
2012 30
2013 24
2014 23
2015 32
2016 24
2017 26
2018 35
2019 46
2020 57
2021 86
2022 69
2023 89
2024 84
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Results by year

Filters applied: . Clear all
Page 1
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R. Jiang L, et al. Cell. 2020 Nov 25;183(5):1219-1233.e18. doi: 10.1016/j.cell.2020.10.045. Cell. 2020. PMID: 33242418 Free PMC article.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progression-free survival of 6.6 months (6.1-9.3) and overall survival of 15.1 months (11.3-18.7). ...Treatment-related deaths occurred in ten (3%) of 356 patients treated with cemipl …
Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progression-free survival of 6.6 months (6. …
Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice.
Zhao J, Jung S, Li X, Li L, Kasinath V, Zhang H, Movahedi SN, Mardini A, Sabiu G, Hwang Y, Saxena V, Song Y, Ma B, Acton SE, Kim P, Madsen JC, Sage PT, Tullius SG, Tsokos GC, Bromberg JS, Abdi R. Zhao J, et al. J Clin Invest. 2022 Dec 15;132(24):e159672. doi: 10.1172/JCI159672. J Clin Invest. 2022. PMID: 36519543 Free PMC article.
Lactobacilli and Bifidobacterium as anti-atherosclerotic agents.
Abdi M, Esmaeili Gouvarchin Ghaleh H, Ranjbar R. Abdi M, et al. Iran J Basic Med Sci. 2022 Aug;25(8):934-946. doi: 10.22038/IJBMS.2022.63860.14073. Iran J Basic Med Sci. 2022. PMID: 36159325 Free PMC article. Review.
Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosis. Therefore, this study aimed to review the anti-atherosclerotic effects of Lactobacilli and Bifidobacterium via improving lipid profile an …
Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosi …
Regulatory B Cells in Autoimmune Diabetes.
Ben Nasr M, Usuelli V, Seelam AJ, D'Addio F, Abdi R, Markmann JF, Fiorina P. Ben Nasr M, et al. J Immunol. 2021 Mar 15;206(6):1117-1125. doi: 10.4049/jimmunol.2001127. J Immunol. 2021. PMID: 33685919 Review.
Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model.
Azizi F, Amouzegar A, Khalili D, Abdi H, Tohidi M, Hedayati M, Cheraghi L, Mehrabi Y, Takyar M. Azizi F, et al. Endocrine. 2024 May;84(2):577-588. doi: 10.1007/s12020-023-03656-5. Epub 2024 Jan 2. Endocrine. 2024. PMID: 38165576 Clinical Trial.
METHODS: A total of 258 patients were treated with methimazole for a median of 18 months and randomized to discontinuation of the drug(conventional short-term group; n = 128) or continuation of the treatment up to 60-120 months(long-term group; n = 130). ...
METHODS: A total of 258 patients were treated with methimazole for a median of 18 months and randomized to discontinuation of the drug(conve …
675 results